USS Investment Management Ltd Decreases Stake in Zoetis Inc. $ZTS

USS Investment Management Ltd cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 16.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,660 shares of the company’s stock after selling 16,911 shares during the quarter. USS Investment Management Ltd’s holdings in Zoetis were worth $10,357,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Global Wealth Strategies & Associates acquired a new stake in Zoetis in the 4th quarter valued at about $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Zoetis in the fourth quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Zoetis in the third quarter valued at approximately $31,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $30,000. Finally, Elyxium Wealth LLC purchased a new position in Zoetis during the fourth quarter worth approximately $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.9%

Shares of NYSE:ZTS opened at $72.48 on Thursday. The business has a 50-day moving average price of $85.77 and a 200 day moving average price of $109.95. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The company has a market capitalization of $30.39 billion, a price-to-earnings ratio of 12.02, a PEG ratio of 1.12 and a beta of 0.75. Zoetis Inc. has a 12-month low of $71.47 and a 12-month high of $161.77.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the firm posted $1.48 earnings per share. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Insider Buying and Selling at Zoetis

In related news, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction on Wednesday, May 13th. The stock was bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 11,650 shares of company stock valued at $886,384 in the last 90 days. Company insiders own 0.22% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of a number of recent research reports. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Argus reaffirmed a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. JPMorgan Chase & Co. reduced their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $126.92.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: One recent note suggested Zoetis’ index shift could reinforce its competitive moat in companion-animal health, which supports the long-term investment case. Zoetis (ZTS) Index Shift: A Harbinger for Its Competitive Moat in Companion-Animal Health?
• Neutral Sentiment: Barclays cut its price target on Zoetis to $85 from $136 and kept an equal-weight rating, signaling a more cautious valuation view but not a bearish downgrade. Barclays price target cut on Zoetis
• Neutral Sentiment: TD Cowen lowered its target to $104 from $150 while maintaining a buy rating, reflecting softer near-term expectations while still seeing upside from current levels. TD Cowen price target cut on Zoetis
• Neutral Sentiment: Multiple firms reminded investors about the July 27 deadline to join the Zoetis securities class action, keeping legal uncertainty in focus for shareholders. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action
• Neutral Sentiment: Analyst commentary also highlighted that stabilization in Zoetis products may still be several quarters away, which adds to the view that fundamentals could remain challenged in the near term. This analyst thinks stabilization for Zoetis’ products could be several quarters away
• Negative Sentiment: The series of class-action notices may raise investor concern about alleged misstatements tied to product adoption, adding a legal overhang to the shares. ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.